MALCOLM JAN 4

What Happened
Malcolm Jan, a director of United Therapeutics (UTHR), sold 50 shares on 2026-02-17 in an open-market disposition. The shares were sold at $474.68 per share for aggregate proceeds of $23,734. This was a sale (not a purchase), which is often routine for insiders.

Key Details

• Transaction date: 2026-02-17
• Type: Sale — open market (coded "S")
• Shares sold: 50 at $474.68 per share
• Proceeds: $23,734
• Shares owned after transaction: Not specified in the provided filing
• Footnote: Sale executed pursuant to a Rule 10b5-1 trading plan established by the reporting person on 2025-09-11
• Timeliness: Filing covers the same date as the transaction (no late filing indicated)

Context
A 10b5-1 plan lets insiders sell pre-arranged trades and is commonly used to avoid questions about trading on material nonpublic information; it does not necessarily indicate a change in the insider’s view of the company. Sales are generally less informative than purchases for signaling sentiment.